Literature DB >> 12646035

A comparison of physiochemical property profiles of development and marketed oral drugs.

Mark C Wenlock1, Rupert P Austin, Patrick Barton, Andrew M Davis, Paul D Leeson.   

Abstract

The process of drug discovery applies rigorous selection pressures. Marketed oral drugs will generally possess favorable physiochemical properties with respect to absorption, metabolism, distribution, and clearance. This paper describes a study in which the distributions of physiochemical properties of oral drugs in different phases of clinical development are compared to those already marketed. The aim is to identify the trends in physiochemical properties that favor a drug's successful passage through clinical development and on to the market. Two libraries were created, one of current development oral drugs and one of marketed oral drugs. Statistical analysis of the two showed that the mean molecular weight of orally administered drugs in development decreases on passing through each of the different clinical phases and gradually converges toward the mean molecular weight of marketed oral drugs. It is also clear that the most lipophilic compounds are being discontinued from development.

Mesh:

Substances:

Year:  2003        PMID: 12646035     DOI: 10.1021/jm021053p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  70 in total

1.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

2.  Drug discovery: Chemical beauty contest.

Authors:  Paul Leeson
Journal:  Nature       Date:  2012-01-25       Impact factor: 49.962

Review 3.  Finding the sweet spot: the role of nature and nurture in medicinal chemistry.

Authors:  Michael M Hann; György M Keserü
Journal:  Nat Rev Drug Discov       Date:  2012-04-30       Impact factor: 84.694

Review 4.  The influence of the 'organizational factor' on compound quality in drug discovery.

Authors:  Paul D Leeson; Stephen A St-Gallay
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

Review 5.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

6.  Quantifying the chemical beauty of drugs.

Authors:  G Richard Bickerton; Gaia V Paolini; Jérémy Besnard; Sorel Muresan; Andrew L Hopkins
Journal:  Nat Chem       Date:  2012-01-24       Impact factor: 24.427

7.  A novel strategy for physiologically based predictions of human pharmacokinetics.

Authors:  Hannah M Jones; Neil Parrott; Karin Jorga; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers.

Authors:  Aurélien Monge; Alban Arrault; Christophe Marot; Luc Morin-Allory
Journal:  Mol Divers       Date:  2006-09-21       Impact factor: 2.943

9.  Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.

Authors:  Wenhui Hu; Hantamalala Ralay Ranaivo; Saktimayee M Roy; Heather A Behanna; Laura K Wing; Lenka Munoz; Ling Guo; Linda J Van Eldik; D Martin Watterson
Journal:  Bioorg Med Chem Lett       Date:  2006-10-17       Impact factor: 2.823

10.  Lead-like, drug-like or "Pub-like": how different are they?

Authors:  Tudor I Oprea; Tharun Kumar Allu; Dan C Fara; Ramona F Rad; Lili Ostopovici; Cristian G Bologa
Journal:  J Comput Aided Mol Des       Date:  2007-02-28       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.